a public good project by the
Synthesis
Company
of California

© 2026

Eric Bleickardt | doi.page

0 works0 citations0 h-index

Eric Bleickardt

Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)

Publications by Year

Research Areas

Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, CAR-T cell therapy research, Multiple Myeloma Research and Treatments, Eosinophilic Disorders and Syndromes

Most-Cited Works

→ Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias(2006)1,763 cited
→ Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia(2010)1,574 cited
→ Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma(2015)1,311 cited
→ Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia(2008)487 cited
→ Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma(2020)423 cited
→ Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM(2016)235 cited

→ Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis(2008)

229 cited

→ Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily(2009)211 cited

→ Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study(2015)154 cited

→ Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth(2017)132 cited